ePT--the Electronic Newsletter of Pharmaceutical Technology, Oct 18, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Oct 18, 2012
News
New USP Standards Guide Prescription Container Labels
By Jennifer Markarian
New US Pharmacopeial Convention standards provide a universal approach to organizing labels for prescription containers dispensed by US pharmacists in an effort to improve patient understanding.
Novasep to Build the World's Largest Chromatography Plant
By Amy Ritter
Novasep announced that it will be investing EUR 30 million ($39 million) to build what will be the world's largest chromatography plant for the production of large volumes of commercial APIs.
Teva Opens New Sterile Plant in Hungary
By Adeline Siew, PhD
Teva has invested $110 million in a new sterile plant in Hungary. The company hopes the plant will strengthen the company's role in Hungarian drug development.
GSK Encourages Open Innovation and R&D
By Stephanie Sutton
GlaxoSmithKline has outlined the measures it is taking as part of a new open innovation approach to R&D, including opening up its tuberculosis compound library, investing in its open laboratory in Spain, and sharing detailed clinical trial data with researchers.
Grad Student Research Sparks Innovation through AAPS Awards
By Angie Drakulich
At this week's AAPS 2012 Annual Meeting in Chicago, graduate students across the country are being honored for their research and work in bio/pharmaceutical innovation. Pharmaceutical Technology had the chance to talk with a few of the recipients.
Week of October 15, 2012: Catalent Licenses NJIT Taste-Masking Technology; MicroConstants Completes FDA Inspection; and More
Catalent Licenses NJIT Taste-Masking Technology; MicroConstants Completes FDA Inspection; and More.
Regulatory Roundup: Week of October 15, 2012
EMA releases guideline on medicinal products for the treatment of schizophrenia.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here